The Microbiome

a Revolution in Treatment for Rheumatic Diseases?

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Purpose of Review: The microbiome is the term that describes the microbial ecosystem that cohabits an organism such as humans. The microbiome has been implicated in a long list of immune-mediated diseases which include rheumatoid arthritis, ankylosing spondylitis, and even gout. The mechanisms to account for this effect are multiple. The clinical implications from observations on the microbiome and disease are broad. Recent Findings: A growing number of microbiota constituents such as Prevotella copri, Porphyromonas gingivalis, and Collinsella have been correlated or causally related to rheumatic disease. The microbiome has a marked effect on the immune system. Our understanding of immune pathways modulated by the microbiota such as the induction of T helper 17 (Th17) cells and secretory immunoglobulin A (IgA) responses to segmented filamentous bacteria continues to expand. In addition to the gut microbiome, bacterial communities of other sites such as the mouth, lung, and skin have also been associated with the pathogenesis of rheumatic diseases. Summary: Strategies to alter the microbiome or to alter the immune activation from the microbiome might play a role in the future therapy for rheumatic diseases.

Original languageEnglish (US)
Article number62
JournalCurrent Rheumatology Reports
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Microbiota
Rheumatic Diseases
Prevotella
Th17 Cells
Secretory Immunoglobulin A
Porphyromonas gingivalis
Gout
Ankylosing Spondylitis
Immune System Diseases
Ecosystem
Mouth
Immune System
Rheumatoid Arthritis
Bacteria
Lung
Skin

Keywords

  • Ankylosing spondylitis
  • Microbiome
  • Mucosal immunity
  • Psoriatic arthritis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

The Microbiome : a Revolution in Treatment for Rheumatic Diseases? / Rosenbaum, James (Jim); Asquith, Mark.

In: Current Rheumatology Reports, Vol. 18, No. 10, 62, 01.10.2016.

Research output: Contribution to journalReview article

@article{d21da63dc34b4c26bd8ddaf9c89f3183,
title = "The Microbiome: a Revolution in Treatment for Rheumatic Diseases?",
abstract = "Purpose of Review: The microbiome is the term that describes the microbial ecosystem that cohabits an organism such as humans. The microbiome has been implicated in a long list of immune-mediated diseases which include rheumatoid arthritis, ankylosing spondylitis, and even gout. The mechanisms to account for this effect are multiple. The clinical implications from observations on the microbiome and disease are broad. Recent Findings: A growing number of microbiota constituents such as Prevotella copri, Porphyromonas gingivalis, and Collinsella have been correlated or causally related to rheumatic disease. The microbiome has a marked effect on the immune system. Our understanding of immune pathways modulated by the microbiota such as the induction of T helper 17 (Th17) cells and secretory immunoglobulin A (IgA) responses to segmented filamentous bacteria continues to expand. In addition to the gut microbiome, bacterial communities of other sites such as the mouth, lung, and skin have also been associated with the pathogenesis of rheumatic diseases. Summary: Strategies to alter the microbiome or to alter the immune activation from the microbiome might play a role in the future therapy for rheumatic diseases.",
keywords = "Ankylosing spondylitis, Microbiome, Mucosal immunity, Psoriatic arthritis, Rheumatoid arthritis",
author = "Rosenbaum, {James (Jim)} and Mark Asquith",
year = "2016",
month = "10",
day = "1",
doi = "10.1007/s11926-016-0614-8",
language = "English (US)",
volume = "18",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "10",

}

TY - JOUR

T1 - The Microbiome

T2 - a Revolution in Treatment for Rheumatic Diseases?

AU - Rosenbaum, James (Jim)

AU - Asquith, Mark

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Purpose of Review: The microbiome is the term that describes the microbial ecosystem that cohabits an organism such as humans. The microbiome has been implicated in a long list of immune-mediated diseases which include rheumatoid arthritis, ankylosing spondylitis, and even gout. The mechanisms to account for this effect are multiple. The clinical implications from observations on the microbiome and disease are broad. Recent Findings: A growing number of microbiota constituents such as Prevotella copri, Porphyromonas gingivalis, and Collinsella have been correlated or causally related to rheumatic disease. The microbiome has a marked effect on the immune system. Our understanding of immune pathways modulated by the microbiota such as the induction of T helper 17 (Th17) cells and secretory immunoglobulin A (IgA) responses to segmented filamentous bacteria continues to expand. In addition to the gut microbiome, bacterial communities of other sites such as the mouth, lung, and skin have also been associated with the pathogenesis of rheumatic diseases. Summary: Strategies to alter the microbiome or to alter the immune activation from the microbiome might play a role in the future therapy for rheumatic diseases.

AB - Purpose of Review: The microbiome is the term that describes the microbial ecosystem that cohabits an organism such as humans. The microbiome has been implicated in a long list of immune-mediated diseases which include rheumatoid arthritis, ankylosing spondylitis, and even gout. The mechanisms to account for this effect are multiple. The clinical implications from observations on the microbiome and disease are broad. Recent Findings: A growing number of microbiota constituents such as Prevotella copri, Porphyromonas gingivalis, and Collinsella have been correlated or causally related to rheumatic disease. The microbiome has a marked effect on the immune system. Our understanding of immune pathways modulated by the microbiota such as the induction of T helper 17 (Th17) cells and secretory immunoglobulin A (IgA) responses to segmented filamentous bacteria continues to expand. In addition to the gut microbiome, bacterial communities of other sites such as the mouth, lung, and skin have also been associated with the pathogenesis of rheumatic diseases. Summary: Strategies to alter the microbiome or to alter the immune activation from the microbiome might play a role in the future therapy for rheumatic diseases.

KW - Ankylosing spondylitis

KW - Microbiome

KW - Mucosal immunity

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84988448084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988448084&partnerID=8YFLogxK

U2 - 10.1007/s11926-016-0614-8

DO - 10.1007/s11926-016-0614-8

M3 - Review article

VL - 18

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 10

M1 - 62

ER -